We run the machine, they govern the medicine

Meridian holds about sixty per cent of the hospital and owns outright everything that is not the practice of medicine. The land, the building, the plant, the power, the water, the estate, the logistics, the automation, the measurement, and all procurement and supply. That part is shared with nobody.

The state holds between ten and twenty per cent. It contributes land, the licence route and regulatory alignment rather than cash, credited at a higher rate per pound than money is, and it takes its return entirely in treatment rather than in dividends. The size of its share is the floor under how much of this hospital’s capacity goes to patients who are not paying out of their own pocket.

Three clinical partners hold the balance, roughly a quarter between them, as bought stakes carrying a preferential return. They do not have to be Nigerian and the recommendation is that they are not all of one kind. They sit on the clinical body, where Meridian holds a fixed quarter of the vote and the partners divide the rest between them by invested ratio, and where a tied vote is resolved by Meridian’s veto.

There are no private investors. Meridian underwrites any partner seat that goes unsubscribed, so the raise closes on schedule rather than waiting on three separate boards.

Staffing is unchanged from the staffing answer and is not what the partners are for. The group outbids to open and then builds the academy, which is what eventually returns more clinicians to the country than were taken out of it. Shared working with partner institutions adds clinical time alongside that, and adds most when the partner is foreign, because then the time was never Nigerian to begin with.

One sentence contains the whole argument. The group runs the machine, the medicine is governed by institutions that do not work for the group, and the largest single claim on this hospital’s capacity belongs to people who cannot pay for it.

The obvious structure is the reverse of this one. A hospital group keeps clinical management, because that is what a hospital is for, and contracts out the building to somebody who does buildings. Almost every private hospital is arranged that way.

It is wrong here for a reason this study has been assembling for twenty pages without naming it. Look at what the work has actually been about. Bed turnaround as real capacity. Walking distance priced in person years. Ring fenced theatre sessions. Safety stock as a safety control. Seven layers of supply verification. Power as a clinical requirement. Smart cabinets and lot level traceability. The queueing arithmetic that decides how big the place is.

None of that is medicine. All of it is the machine the medicine runs on, and it is the entire content of this group's expertise. Meridian does not have a faculty. It has an operating system, and an operating system is the thing that actually transfers between hospitals, because it lives in process, design and measurement rather than in people.

Which corrects something this study said earlier about its own product. The transferable asset is not the clinical standard. Clinical standards are embodied in clinicians and they walk out of the building every evening. The transferable asset is the substrate, and the substrate is exactly what the group should own outright and never share.

So the division is not a compromise about control. It is each party holding the thing it actually has. The group has an operating system and no faculty. The partner institutions have clinical standing, accreditation and peer review, none of which can be bought at any price, and in the foreign case a name that answers the trust objection directly. The state has the land and the licence route and nothing else anybody needs. Nobody is giving anything away.

The board paper calls the extraction charge decisive, and the brief weights it at twenty eight per cent for the same reason: it is the only criterion where a structure can change the sign of the outcome rather than its size.

The staffing route does not change and should not be misread from this page. The group outbids to open, and then builds the academy, exactly as the staffing answer sets out. Shared working with partner hospitals exists alongside it and is a real source of clinical time, but it is a supplementary route rather than the establishment. A hospital cannot be staffed on other institutions’ goodwill and should not pretend otherwise in its own constitution.

So the charge has to be answered rather than avoided. The answer is not that nobody is hired away from anybody, because people are. It is that the country ends up with more clinicians than it started with. Taking someone and returning nothing is extraction. Taking someone and returning more than you took is a transfer with interest, and the distinction is arithmetic rather than rhetorical.

The arithmetic is below and it is not flattering in the early years, which is why it is worth printing. Consultant grade is the slowest thing a school produces: specialty training runs about six years before anybody qualifies, and a fifth of those who do will emigrate anyway. So the country is genuinely down for a stretch, and the table says by how many and for how long rather than gesturing at eventual repayment.

Two things follow from that trough, and they are the reason this page exists at all. The first is that the deficit years need covering by something other than a promise, which is what the state’s share does: the catchment gets capacity now, as a shareholder return, rather than after the academy matures. The second is that shared working adds clinical time during exactly those years without taking anybody, and it adds the most when the partner is not Nigerian, because a foreign consultant’s session is capacity the country did not previously have at all.

It is worth being precise about the limit. The repayment is real but it is deferred, and the people in the deficit years are not the people who benefit afterwards. No structure makes that disappear. What this one does is shorten the trough, cover it while it lasts, and put the obligation to clear it in the hands of a shareholder who loses something if it is not cleared.

One majority owner, three clinical partners holding real equity, a state shareholder that never takes cash, one shared governing body, and a single deliberate absence.

That absence is a decision rather than a gap. The instruction put government and private investors in the comparator set. Government is in, on terms set out below that make it a shareholder without making it a voter. Private investors are declined, for a reason that is in the brief rather than in anybody’s prejudice: they bring money the group does not need and an interest in relaxing exactly the commitments the whole exercise exists to protect.

Declining them is only available because of a fact established on the entity page. The group sold its other hospitals and is holding the proceeds, so it can fund the majority share itself and underwrite the partner tranche as well. A group without that position would have to take capital on somebody else’s terms and would get a different structure. That is a real limit on how generally this answer applies and it is stated again in the shortfalls.

Four kinds of holder, four positions in the stack, and four different things being bought.

Every party holds a stake, including the one supplying no cash at all, and that is deliberate rather than generous. A partner with no stake can reduce its sessions next year at no cost to itself, and an earlier version of this proposal had exactly that weakness. A partner that has bought in has something to lose, and a hospital whose clinical supply rests on goodwill rests on nothing.

The partner hospitals take a preferential return at a modest fixed rate, ahead of Meridian in the queue and below it in rate. They are buying a yield and a relationship rather than a growth asset. Three at most, because beyond that the clinical body stops being a governing group and becomes a forum. What has to be said plainly is the size of the cheque: a quarter of the hospital between three institutions is tens of millions, and the earlier suggestion on this page that it could be funded out of the revenue share their own clinicians generate does not survive contact with the arithmetic in the next chapter.

The state is the interesting one and it is where the structure earns its keep. It contributes what it actually has, which is land, the licence route and regulatory alignment, rather than money it does not have. That contribution converts into shareholding at a deliberately higher rate than cash, which is set out in full in the next chapter, and it lands the state somewhere between ten and twenty per cent. And it does not extract its return.

That last provision is the most consequential sentence in this proposal. The state’s dividend is taken in treatment: a share of capacity, drawn as of right, for patients who are not paying out of their own pocket. The ethics paper concedes that a voluntary free care share is charity a board can quietly reduce in a difficult year and that the group grades itself on it. This converts it into a shareholder return. Withholding it is no longer a policy adjustment, it is failing to pay a stakeholder what it is owed, and the counterparty has standing, lawyers and an interest in noticing.

Which is how the catchment gets covered in the years the academy has not yet repaid anything. Between a tenth and a fifth of this hospital’s capacity goes to patients who are not paying out of their own pocket, and it goes to them as a shareholder distribution rather than as a charitable allocation. That is a floor rather than a gesture. It is not a majority of the hospital and should never be described as one, and it is still the only instrument on this site that the people with the least money actually hold.

It also fixes something the brief called structural. Instruction 02 weights enforceability from outside at eighteen per cent precisely because nobody currently holds the group to anything. A shareholder whose entire return is the thing the commitments protect is the first party in this whole study with both the standing and the motive to enforce them.

Nobody else is admitted in the first round. No institutional equity, no diaspora placement and no clinician equity yet, for the reason the instruction itself gave: each of them adds a party with a direct financial interest in reducing exactly the return the state has agreed to take. Clinician equity remains attractive against the counter offer problem and it belongs in a later round, once the commitments are entrenched and a new shareholder cannot vote them down.

Meridian keeps the majority at about sixty per cent, so control here is both proportional and constitutional: the shareholding, plus reserved powers over the estate, procurement and supply, plus a fixed quarter of the clinical vote. Worth noting that these are three separate instruments doing three separate jobs, and an investor will ask why all three are needed. The answer is that the first survives a sale of shares, the second survives a change of clinical direction, and the third survives neither on its own.

The shareholdings are set by intention rather than by whoever writes the largest cheque. Meridian holds about sixty per cent, the state between ten and twenty, and the clinical partners the balance between them. That is the structure the group wants, and the job of the capital arrangement is to reach it.

The stack is therefore denominated in credits rather than pounds, and the conversion rate is not the same for everybody. Every pound of capital from Meridian or a partner hospital earns four credits. Every pound the state contributes earns ten.

Because the shares are fixed, the rate does not decide who owns what. It decides what each party has to put in to get there, and the state’s higher rate is what allows it to reach a real holding on a contribution it could not otherwise make. The land is valued honestly and then weighted deliberately, and keeping those two operations separate is what makes the arrangement survive an audit.

The reason for the multiplier is not generosity and should not be argued as though it were. What the state contributes is the part of this project that cannot be bought at any price: land at a location the trust argument requires, the licence route, and regulatory alignment. A rate reflecting only the market value of the acreage would price the scarce thing as though it were the abundant one. Four and ten is a judgement about what is actually hard to obtain, and the group should be willing to defend it line by line.

It should also be honest about who pays for that judgement. The multiplier is a transfer from the cash holders to the mission, it has a size, and the table below puts a number on it. An investor told this at the outset will accept it as the price of the site and the licence. An investor who works it out afterwards will treat it as something that was hidden.

Meridian underwrites the partner tranche. If a seat is not taken up, the group pays for it and the raise closes on schedule rather than waiting on an institution that is still in committee. That is the right commitment to make, because a capital structure whose closing depends on three separate foreign boards agreeing in the same quarter is not a structure, it is a hope.

It does need one clause to stop it eating the thing it protects. Meridian already holds a fixed quarter of the clinical vote and the partners divide the rest; if underwritten shares carried clinical votes with them, then a partner failing to subscribe would hand the group both the equity and the say, and a structure built to put clinical direction beyond the funder would be undone by the funder writing a larger cheque. So underwritten stock carries the economics and not the clinical vote, and it is held for onward sale to an incoming partner rather than retained. The backstop guarantees the closing. It must not be allowed to guarantee control.

And because the state’s return is drawn entirely in treatment, the size of its share is the size of the floor under coverage for the catchment. Ten per cent and twenty per cent are materially different promises, and the group should decide which it is making before it goes into the room rather than settling it as a residual.

One thing the multiplier deliberately does not touch is the clinical vote. Meridian holds a fixed quarter of that and the partner hospitals divide the rest between themselves; the state does not vote clinically at all, whatever its shareholding. Credits buy economic interest and the mission lock. They do not buy a say in how medicine is practised, and the two should never be argued in the same meeting.

Shared clinical oversight is the hardest part of this arrangement and the part most likely to be fudged, so it is set out as a mechanism rather than as a principle. The thresholds below are negotiating positions. The mechanism is not.

The body governs by voting, and the vote does three things: it sets clinical direction, it appoints the Chief Medical Officer, and it is available on any clinical matter a member refers to it.

The weighting is the part that carries the argument, and it is deliberately not proportional to money. Meridian holds a fixed quarter of the clinical vote, granted by the constitution rather than bought, and its stake is excluded from the calculation entirely. The partner hospitals divide the remaining three quarters between themselves by the ratio of what each has invested. The group funds the entire hospital and holds a minority of the vote on how medicine is practised in it, which is the whole proposition stated in one sentence.

That is not modesty, it is the only arrangement that makes the partners real. Weight the clinical vote by capital and Meridian wins every clinical argument by having paid for the building, and the partners are advisers with a voting card. Excluding its stake is what converts a consultation into a governing body, and it is the price of the clinicians the group cannot otherwise get.

Where the partners tie, Meridian has the veto. That completes the shape: it cannot impose, because a quarter is not a majority and its money buys it no more of the vote, and it cannot have something forced on it on an even split either. Every change of clinical direction requires somebody to be persuaded rather than outnumbered.

The veto does one thing that has to be fenced off, and it is the hazard this site has been describing in other currencies for twenty pages. A motion to raise a clinical standard usually costs money, and the party that pays for the hospital can block it on a tie for reasons that are financial while the vote looks clinical. That is the ring fenced theatre session being removed by somebody reading a utilisation report, arriving in a boardroom instead of on a ward.

So the carve out. Where the Chief Medical Officer certifies that a motion is required on patient safety grounds, the veto does not apply and a tie carries it. That keeps the veto for direction, strategy and appointments, which is what it is for, and removes it from the one place it could do harm. It also gives the officer a specific power rather than a general one, which is the right shape for a safety mechanism.

The appointment of the officer is the load bearing vote and it needs a supermajority. The reason is practical rather than constitutional. The consultants working in this hospital are employed by the partner institutions, and an officer a substantial part of the body voted against has no authority over them at all. Legitimacy here has to be collective because the staff are.

And then the officer runs the hospital. Accountability cannot be held by a committee, and a structure that leaves it with one will discover that in front of a coroner. The resolution is not to give the group the appointment; it is to let the body appoint and the officer act. The vote confers the mandate, and the mandate is exercised by a person.

Which produces the two rows in the table that do the safety work. A clinical matter can be referred to the body, and the body advises, and the officer decides and records the decision against that advice. Anything happening now is not voted on at all. A hospital cannot convene at three in the morning, and an arrangement that implies otherwise is unsafe on paper long before it is unsafe on a ward.

One asymmetry is not negotiable and should be drafted first. Raising a clinical standard takes a majority. Lowering one takes unanimity of the whole body and a named clinician’s written justification on the record. That is the rule the standards page already sets, which is that objectives never fall and specifications are re-derived, given a voting threshold so that it survives the year somebody is under cost pressure.

The final row is the quiet one. Operational matters are not the body’s at all: the estate, procurement, the supply chain and the non clinical establishment are Meridian’s alone. The body sets clinical requirements and the group decides how they are met. Without that line the votes leak sideways into the machine, and the reason this structure works is that the machine has one owner.

Twenty five per cent sounds like a minority position and a veto sounds like a safeguard. Put the two together and work out which coalitions can actually carry a motion, and the arrangement turns out to be considerably stronger than either word implies. This is worth doing on paper before it is agreed, because none of it is obvious from the clauses.

A coalition carries a motion only by exceeding half of the vote outright, since an exact half is a tie and a tie is vetoed. Because Meridian’s quarter is fixed, that condition reduces to a threshold on invested capital that does not depend on the amounts at all: a group of partners must hold more than two thirds of the partner capital to act over the veto.

The consequence in the first row is the one to sit with. If the three partners invest equally, no two of them can carry anything. Two thirds of the partner capital produces exactly half of the vote, which is a tie, which Meridian vetoes. Equal stakes mean clinical direction against Meridian’s wishes requires all three partners unanimously, and Meridian plus any single partner can stop anything at all.

That is a much harder position than the constitution appears to grant, and if it is the intention it should be stated rather than discovered. If it is not the intention, the fix is in the stakes rather than the thresholds: partner holdings have to be deliberately uneven for a two partner coalition to be able to act.

Which gives the third row, and the opposite failure. A partner holding more than two thirds of the partner capital carries motions on its own, over Meridian and over the other two partners together. The cap of three partners was set to keep the body governing rather than debating; the distribution of stakes within that three decides whether the body has one voice in it or several, and that is a question about the capital structure rather than about clinical governance.

The practical instruction is short. Do not agree the voting rules and the stake sizes in separate conversations. They are the same conversation, and this table is what it looks like when it is held once.

The line is not clinical against non clinical, and drawing it there is the commonest way this structure fails.

Portering, cleaning and bed turnaround look like facilities and are capacity. A bed is not a bed again until somebody has cleaned it, and this study has already put a number on what that returns across a hospital. They sit with the group, which is what the group is for, and there is no contract boundary between them and the wards because there is only one company on that side of the line.

That is the quiet advantage of this arrangement over the version with an outsourced estate. There is no facilities contract. Nobody is measuring cleans completed while the hospital needs beds returned. Every operational function reports to one organisation whose entire expertise is flow, and the only boundary in the building is the one between the machine and the medicine.

Procurement deserves its own note. Buying at group scale, with verification, testing and a single accredited chain, is the only serious answer to the counterfeit medicines problem, and it improves with every hospital the group adds. Partner institutions buying through it is a benefit worth real money to them, and it is the kind of benefit that binds a partnership more durably than a revenue share.

Four rows are genuinely contested and the table says so rather than pretending otherwise. The sharpest is nursing establishment, which is a clinical safety decision that sits in the cost base the group carries. Both sides have a legitimate claim, this proposal gives it to the joint body, and the first difficult budget will test whether that holds.

A partner hospital is being asked to buy a stake in a hospital it does not control and to let some of its consultants work there, which on the face of it is a thing to resist rather than to sign. What it receives differs depending on where it is, and the next chapter takes that apart.

What it receives is specific. A shareholding of real size, carrying a preferential return at a modest fixed rate, ahead of Meridian in the queue and behind nothing. Sessions for its clinicians in a facility its own estate may not be able to provide. A share of the private revenue those clinicians generate, flowing to the institution rather than only to the individual, which is the difference between a partnership and a moonlighting arrangement. Training placements and a route into the academy. Access to the group’s procurement, which is worth real money and gets better as the group grows. And seats on the body that sets the clinical standard, where its vote is weighted by what it put in.

What the group receives is not headcount, and this is where the earlier draft of this page overreached. The hospital is staffed by the route the staffing answer sets out. What a partner brings is the things capital cannot buy: peer review by people who do not work for us, a recognised institution’s name on the clinical governance, the accreditation standing the academy will need, and clinical time during the years the academy has not yet produced anybody. The family testimony on this site says the barrier is evidence and accountability rather than capability, and standards set jointly with an established teaching institution are a claim a new entrant cannot otherwise make on day one.

It is worth naming what this does to the trust ramp, because it is the second most valuable feature of the structure after the extraction charge. The board paper treats the slow ramp as a ground against the project: trust cannot be bought and takes years of published performance. Partnering with an institution that already has it is the one legitimate shortcut, and it is available immediately.

Everything above has quietly assumed the clinical partners are Nigerian teaching hospitals. That assumption was never argued for and it does not hold. The seats can be filled from anywhere, and dropping the assumption changes three of the hardest findings on this page.

It answers most of the affordability problem. A quarter of the hospital is tens of millions, which is a serious ask of a Nigerian teaching hospital and an ordinary investment for an international academic centre or a Gulf or Indian hospital group. The stake stops being a favour the group has to finance and becomes a transaction the partner can actually do.

It answers the trust question far more directly than a local partner can. The family testimony on this site says the barrier is evidence and accountability rather than capability, and that a patient who can afford to leave will leave. A Nigerian name on the clinical governance does not speak to that patient, because their objection is to Nigerian provision as a category. A recognised foreign institution auditing the standards is the one claim that meets the objection where it actually sits, and it is available on day one.

And it changes the sign of the extraction argument. A foreign partner’s consultants doing sessions here do not deplete Nigerian clinician supply; they add to it. The deficit the previous chapter puts at its trough in year five is covered in part by clinical time that was never Nigerian to begin with. That is not a repayment of the debt, which only the academy clears, but it is cover while the debt is outstanding, and it is the strongest operational reason to look abroad.

The costs are real and should not be buried. Foreign consultant time is priced in hard currency at a multiple of local rates, which lands on the operating model rather than on the capital structure. Every clinician needs temporary registration. And a seat on the body that sets clinical direction would be held by an institution that does not live with the consequences of its votes, which is a different thing from a partner down the road whose own patients are affected by what it decides here.

There is also a political cost that the group should price rather than dismiss. A hospital built on state land, granted at a deliberately favourable credit rate, with clinical governance held by foreign institutions, is a story that writes itself and it will be written. The answer is not to avoid foreign partners. It is to keep a Nigerian teaching hospital in the structure so that the sentence is never true.

Which is the recommendation. Not three local partners, which is what this page assumed without saying so, and not three foreign ones either. At least one Nigerian teaching hospital for accreditation, trainees, licensure and standing, and at least one recognised foreign institution for capital, standards and the trust argument. The third seat is the one to hold open, because it is the one that should be filled by whichever of those two turns out to be the binding constraint.

The criteria and weights come from instruction 02 and were fixed before this proposal was drawn. The weights are quoted; only the scores are ours, and they are a judgement rather than a measurement.

Read the rows. The first moves furthest, from two to seven, and it is worth being clear about why it stops at seven. People are still hired away from public hospitals, so the charge is answered rather than avoided: the academy returns more than was taken, and the state’s capacity share covers the catchment while that is outstanding. An earlier draft of this page scored it nine on the claim that nobody was hired from anywhere, which was not true. The second row moves because the state holds a share whose entire return is the thing the commitments protect, which makes it the first party in this study with both the standing and the motive to enforce them.

Three rows move the wrong way and all three are honest costs. Control of the operating standard is eight rather than ten, because the clinical standard is genuinely shared and that is a real transfer, even though the operating standard is held outright. The exit drops to six, which deserves more attention than it usually gets: a buyer inherits a hospital whose clinicians belong to other institutions, minority holders with preferential rights, and a state shareholder taking its return in beds. And deliverability takes the largest fall of all.

That fall is from ten to six, and an earlier draft of this page claimed the opposite. It was written when the structure had no equity negotiation, no regulated raise, no government counterparty and nothing to value. It now has all of those. A state stake earned in kind at a credit rate somebody has to agree, three partner stakes to price and place, foreign institutions whose boards do not move quickly, and an underwriting commitment that has to be sized before any of it is signed. None of that is fatal. All of it is slower than one owner writing a cheque, and the page should not pretend otherwise.

Only one partner willing to engage. The structure needs more than one from the outset, because a hospital whose entire clinical supply rests on a single relationship has traded the extraction charge for a dependency, and the second is easier to see and harder to survive.

Partner institutions that will sign sessions but not shared governance. Sessions alone make this a staffing agency arrangement with better paperwork. The whole ethical argument rests on the partners owning the clinical standard their people work to, and a proposal that delivers only the sessions should be reported as having failed rather than as having partly succeeded.

A regulator that will not licence shared clinical governance. This is the technical risk that could end the structure and nobody has tested it. The licensing question is whether a single accountable clinical officer inside a jointly governed body satisfies the regulator, and it is a conversation to have before anything else.

And evidence that the capital requirement is materially larger than the disposal proceeds and the partner tranche together. The group funds the majority itself and underwrites the rest, so the structure already assumes it can absorb a shortfall. If it cannot, the choice is between private investors, which the brief warns makes the enforcement problem worse, and a smaller hospital. On this analysis the smaller hospital is the better answer, and that should be said now rather than discovered later.

Eleven, which is a good many more than this page started with. They multiplied as the structure got more specific rather than because it got worse, and that is the ordinary direction of travel: a vague proposal has few visible weaknesses because there is not enough of it to inspect.

Three are marked as serious and they are the ones that decide whether the rest holds. Deadlock costs Meridian less than it costs the partners, because the group runs the hospital whatever the clinical body resolves. A foreign partner treating patients who currently fly out holds a vote over how good its own competitor becomes. And the underwriting that guarantees the raise closes is the same instrument that would hollow out the clinical body if it were ever drawn in full. The accountability question that dominated the earlier draft of this section is not among them any more, because the votes chapter settles it: the body sets the standard and one named officer carries it.